|
12th Thomas Ashworth
Symposium 4th to 6th November 2026 PERTH AUSTRALIA |
12th Thomas Ashworth CTC & Liquid Biopsy Symposium
Key Dates
Symposium dates: 4th to 6th November 2026
Early bird registration & abstract submission opens 8th June 2026
Symposium dates: 4th to 6th November 2026
Early bird registration & abstract submission opens 8th June 2026
Welcome
On behalf of the TAS2026 organising committee it is our pleasure to welcome colleagues, friends and supporters to the 12th Thomas Ashworth CTC & Liquid Biopsy Symposium (TAS2026) in Perth, WA,
The Symposium will be held over three days from the 4th to the 6th November 2026 at the Harry Perkins Institute of Medical Research located within the QEII Medical Centre precinct in Nedlands. The Institute is a world-class facility and offers a contemporary, purpose-built environment featuring advanced lecture theaters, breakout spaces and expansive communal areas ideal for scientific exchange. The venue is easily accessible, situated just minutes from central Perth and well connected to public transport, making attendance convenient for both local and visiting delegates. We are delighted to have secured this outstanding venue and maintain the goal of affordability with a particular emphasis for students, early-career researchers and full registrant participant at a reasonable fee. Our goal is to ensure broad participation and to create an inclusive, engaging environment for the liquid biopsy community.
The theme for this year’s Symposium is “Pushing the Limits: Technology at the Edge of Discovery”, and it will dive into the groundbreaking technological advances driving liquid biopsy research, such as next generation (NGS) sequencing innovations, ultrasensitive detection platforms, AI-powered biomarker discovery, and emerging multiomics approaches that are reshaping how we understand disease and bringing liquid biopsy closer to routine clinical application.
The aim of the Symposium is to enrich our understanding of the clinical application of liquid biopsy and improve patient outcomes, as well as provide critical insights into the metastatic process and the broader utility of liquid biopsy in different disease settings. Topics that will be explored include circulating tumour cells, exosomes, methylated ctDNA, assay development, early detection, integration of liquid biopsy into clinical trials and precision oncology, treatment selection and monitoring as well as drug resistance monitoring.
An exciting line up of invited keynote speakers who are international leaders in the field will be showcasing their liquid biopsy research. In addition, invited speakers and speakers selected from submitted abstracts from across Australia, New Zealand and Asia will present their latest research. Two panel discussions are included in the program and are designed to highlight patient perspectives and health professional views with the intent to stimulate debate and are a symposium highlight.
The Symposium will be held over three days from the 4th to the 6th November 2026 at the Harry Perkins Institute of Medical Research located within the QEII Medical Centre precinct in Nedlands. The Institute is a world-class facility and offers a contemporary, purpose-built environment featuring advanced lecture theaters, breakout spaces and expansive communal areas ideal for scientific exchange. The venue is easily accessible, situated just minutes from central Perth and well connected to public transport, making attendance convenient for both local and visiting delegates. We are delighted to have secured this outstanding venue and maintain the goal of affordability with a particular emphasis for students, early-career researchers and full registrant participant at a reasonable fee. Our goal is to ensure broad participation and to create an inclusive, engaging environment for the liquid biopsy community.
The theme for this year’s Symposium is “Pushing the Limits: Technology at the Edge of Discovery”, and it will dive into the groundbreaking technological advances driving liquid biopsy research, such as next generation (NGS) sequencing innovations, ultrasensitive detection platforms, AI-powered biomarker discovery, and emerging multiomics approaches that are reshaping how we understand disease and bringing liquid biopsy closer to routine clinical application.
The aim of the Symposium is to enrich our understanding of the clinical application of liquid biopsy and improve patient outcomes, as well as provide critical insights into the metastatic process and the broader utility of liquid biopsy in different disease settings. Topics that will be explored include circulating tumour cells, exosomes, methylated ctDNA, assay development, early detection, integration of liquid biopsy into clinical trials and precision oncology, treatment selection and monitoring as well as drug resistance monitoring.
An exciting line up of invited keynote speakers who are international leaders in the field will be showcasing their liquid biopsy research. In addition, invited speakers and speakers selected from submitted abstracts from across Australia, New Zealand and Asia will present their latest research. Two panel discussions are included in the program and are designed to highlight patient perspectives and health professional views with the intent to stimulate debate and are a symposium highlight.
Confirmed Keynote Speakers
- Professor Dan Landau, Weill Cornell Medicine and NY Genome Center, New York, USA
- Professor An Hendrix, Cancer Research Institute, Ghert University, Ghert, Belgium
- Associate Professor Margaret Lee, Eastern Health and Western Health, Melbourne, Australia
Who should attend?
The organising committee maintains a philosophy of keeping registration costs as low as possible to encourage attendance and this is only possible through the generous support of our sponsors. So please ensure to visit the exhibitor tables and check out their latest product offerings.
We look forward to seeing you at the Symposium in November.
- Translational/clinical researchers
- Medical oncologists
- Pathologists
- Patient advocates
- Clinical trainees, PhD and other students
- Pharmaceutical and diagnostic sector
The organising committee maintains a philosophy of keeping registration costs as low as possible to encourage attendance and this is only possible through the generous support of our sponsors. So please ensure to visit the exhibitor tables and check out their latest product offerings.
We look forward to seeing you at the Symposium in November.
|
|
Professor Elin Gray and Associate Professor Kevin Spring
Co-convenors 12th Thomas Ashworth CTC & Liquid Biopsy Symposium
Co-convenors 12th Thomas Ashworth CTC & Liquid Biopsy Symposium
Diamond Sponsor
Platinum Sponsors
|
|
Institutional Host
Organizing Committee
Prof. Elin Gray Edith Cowen University, Perth
A/Prof. Kevin Spring Western Sydney University, Ingham Institute, CIAS/ARI (SLHD), Sydney
Dr. Stephen Wong Peter MacCallum Cancer Centre, Melbourne
A/Prof. Therese Becker Ingham Institute, Sydney
Prof Hyun Woo (Henry) Park Yonsei University, South Korea
Dr Anders Skanderup A*Star, Genome Instiute of Singapore (GIS), Singapore
A/Prof Clare Stirzaker Garvan Institute, Sydney
Dr Sandra Fitzgerald University of Auckland, Auckland, NZ
A/Prof. Clare Stirzaker Garvan Institute, Sydney
Dr Jean Winter Flinders University, Adelaide
Prof Chamindie Punyadeer Griffith University, Brisbane
Dr Leslie Calapre. Edith Cowan University, Perth
Dr Rodrigo Carlessi Curtin University, Perth
Dr Lydia Warburton Fiona Stanley Hospital and Edith Cowen University, Perth
Prof. Elin Gray Edith Cowen University, Perth
A/Prof. Kevin Spring Western Sydney University, Ingham Institute, CIAS/ARI (SLHD), Sydney
Dr. Stephen Wong Peter MacCallum Cancer Centre, Melbourne
A/Prof. Therese Becker Ingham Institute, Sydney
Prof Hyun Woo (Henry) Park Yonsei University, South Korea
Dr Anders Skanderup A*Star, Genome Instiute of Singapore (GIS), Singapore
A/Prof Clare Stirzaker Garvan Institute, Sydney
Dr Sandra Fitzgerald University of Auckland, Auckland, NZ
A/Prof. Clare Stirzaker Garvan Institute, Sydney
Dr Jean Winter Flinders University, Adelaide
Prof Chamindie Punyadeer Griffith University, Brisbane
Dr Leslie Calapre. Edith Cowan University, Perth
Dr Rodrigo Carlessi Curtin University, Perth
Dr Lydia Warburton Fiona Stanley Hospital and Edith Cowen University, Perth
|
|
Copyright 2025 ThomasAshworthSymposium